Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial - Wikidata - awgldk - TriplyDB

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

http://www.wikidata.org/entity/Q34571157

about

Statins for the primary prevention of cardiovascular disease Blood pressure targets for hypertension in people with diabetes mellitus Treatment blood pressure targets for hypertension Ezetimibe therapy: mechanism of action and clinical update Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials Carotid Intima Media Thickness, Atherosclerosis, and 5-Year Decline in Odor Identification: The Beaver Dam Offspring Study.Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial.Increased mean carotid intima media thickness in type 2 diabetes mellitus patients with non-blood pressure component metabolic syndrome: A preliminary report.PREVENTION OF ATHEROSCLEROSIS WITH LDL-C LOWERING - LIPOPROTEIN CHANGES AND INTERACTIONS: THE SANDS STUDY How to define prehypertension in diabetes/metabolic syndrome.Blood pressure control in diabetes: temporal progress yet persistent racial disparities: national results from the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.Cost-effectiveness of lower targets for blood pressure and low-density lipoprotein cholesterol in diabetes: the Stop Atherosclerosis in Native Diabetics Study (SANDS) .Statin underuse and low prevalence of LDL-C control among U.S. adults at high risk of coronary heart disease.Carotid intima-media thickness in individuals with and without type 2 diabetes: a reproducibility study.Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial.Achieving lipid targets in adults with type 2 diabetes: the Stop Atherosclerosis in Native Diabetics Study Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience.Vascular biomarkers in the prediction of clinical cardiovascular disease: the Strong Heart Study.Risk Factors of Coronary Artery Disease in Secondary Prevention--Results from the AtheroGene--Study.Comprehensive Cardiovascular Risk Factor Control Improves Survival: The BARI 2D Trial.Assessment of Carotid Artery Stenosis and the Use of Statins.Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients Diabetes and coronary heart disease: a risk factor for the global epidemic.Carotid Intima-media Thickness Measurements: Relations with Atherosclerosis, Risk of Cardiovascular Disease and Application in Randomized Controlled Trials Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive Co Dietary patterns and their association with cardiovascular risk factors in a population undergoing lifestyle changes: The Strong Heart Study.Impact of ezetimibe on atherosclerosis: is the jury still out?Insulin resistance, incident cardiovascular diseases, and decreased kidney function among nondiabetic American Indians: the Strong Heart Study.Management of cardiovascular disease risk factors in older adults with type 2 diabetes mellitus: 2002-2012 literature review.Hypertension 2010: what was new for the cardiologist?The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.What combination therapy with a statin, if any, would you recommend?Optimal therapy in hypertensive subjects with diabetes mellitus.Lipid-lowering effects of ezetimibe and simvastatin in combination.The ezetimibe controversy: implications for clinical practice.The ezetimibe controversy - can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?Cardiometabolic impact of non-statin lipid lowering therapies.Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.

P2860

Q24201513-62F29BC1-E2DD-4027-A615-A74D38C37F7A Q24202854-69285DD1-A720-48EE-B71F-037F4B8A2C37 Q24239956-331883E7-DF9D-44D0-BFFE-707BBF113637 Q24630302-5E7B6727-2C99-4D36-AF8A-C41CC21FF365 Q28546769-73849727-D7A7-4ACD-A2E7-915CB1AC5805 Q30380335-E7366210-DFB7-4A17-8586-85480BFDAFCB Q30464117-C2180C7C-BD82-433F-967D-1042CE38ABA0 Q33574354-DC44CBE3-2227-4827-95B1-46EC1442E032 Q33588399-A679D9F0-98E4-46CF-AB1B-D8B3D0CBB63B Q33610643-22E21BC5-ACCF-4ABA-BF78-21CB5FFCA37D Q33751514-822CC9E2-1694-4E65-871B-6BACB3513D4F Q33789084-9FBACC20-4980-4394-A9E8-EC06FE9BE337 Q33913848-9AF57C7F-A816-470D-8541-32442FEEDBF6 Q33940584-A04F0E23-FE14-4882-811B-F8728D1CDFFC Q34097974-F795B87F-CE10-4F39-BCF6-14ECA1710E64 Q34279210-1314D912-A05D-4925-9605-599600489784 Q34291764-6B20275E-519A-40ED-800B-052737488C25 Q34334828-ECF14F76-D4BE-4FE4-8C3C-70E0ED4B1265 Q35569277-13E38838-6A5F-4D0A-AFA2-9FB1B090FA4B Q35677150-1D68FB65-6454-40D3-9FA0-462859940707 Q35686023-EFC8BD87-032B-43C4-B4CA-94DEEDAFB3CB Q35999237-6EFCC579-9AD6-4873-BF03-6618F5DC0451 Q36065333-B0CE9354-1300-43B9-8059-394DF9ACEB56 Q36134940-98A3BC46-1801-4346-AA32-691CEB0ABFE9 Q36355698-D26AD81E-DB57-4204-B6A9-F59A5620A4AF Q36705497-BB8CF6E9-58C9-4EFE-B301-5F7F7DDE9595 Q36877809-19286526-A016-4F2E-8051-02FEB83A311A Q36906338-8A1B3645-15AA-4715-9B60-AAE139A0AC9A Q37151389-31500DED-1C90-4A80-803D-08EA1BE5F062 Q37193499-6BCD821E-D80C-4D96-8D93-1B2DE383F163 Q37689636-44F1E0B7-F875-4922-8E2B-A4816F6E93FA Q37803231-8EFD633A-214B-4457-B791-E93F929DC5A9 Q37810986-C98DFD60-C27B-4577-A24C-65AB89FFE672 Q37812296-024A15FB-298F-41D9-9AC9-E0068793E02C Q37828455-F3C7B998-8B7F-40B6-89F1-A3657CB637EA Q37859778-B9AFB78F-E4DB-4FCB-91AF-FBBCE9C9553C Q37884287-6CBF20ED-203C-423F-B1A2-3EC3946E5D90 Q38020942-895D05FF-3682-4781-A064-DDC32060885B Q38176275-E96AE477-7C2D-4A98-8015-68A6938471B1 Q38206839-50CA1C4F-3460-4411-A54E-8A5C7A0040A5

P2860

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial

http://www.wikidata.org/entity/Q34571157

description

2008 nî lūn-bûn

@nan

2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Effect of lower targets for bl ...... es: the SANDS randomized trial

@ast

Effect of lower targets for bl ...... es: the SANDS randomized trial

@en

Effect of lower targets for bl ...... es: the SANDS randomized trial

@nl

type

label

Effect of lower targets for bl ...... es: the SANDS randomized trial

@ast

Effect of lower targets for bl ...... es: the SANDS randomized trial

@en

Effect of lower targets for bl ...... es: the SANDS randomized trial

@nl

prefLabel

Effect of lower targets for bl ...... es: the SANDS randomized trial

@ast

Effect of lower targets for bl ...... es: the SANDS randomized trial

@en

Effect of lower targets for bl ...... es: the SANDS randomized trial

@nl

P1433

Q34571157-B2D76D2C-5601-4AF4-930A-787FD58F66B1

P1476

Q34571157-E2E038F4-D111-49A2-ACCF-32E361D141C6

P2093

Q34571157-191B0B88-B940-4B25-9FB3-9E4831565203

Q34571157-2698D8AC-4B99-4418-A644-B9986EB467EF

Q34571157-2C09E4D0-0A35-4245-AC81-434EA2DBFC66

Q34571157-30C99981-D0F4-43FD-B704-53D7B1E911E5

Q34571157-33289E7E-C8CA-4D8C-9501-27713CB1A168

Q34571157-3335BDBB-50C1-4DF3-AE43-BE5B780DDCBC

Q34571157-429A9833-017C-41C5-B67B-F146E8D15BBE

Q34571157-640576EF-9567-4284-AD3B-A0AB8631A697

Q34571157-72E89766-74BB-4210-8831-E82E9A78E020

Q34571157-77F413B7-CE44-4D49-B8C0-92D68963FEA7

P2860

Q34571157-010DEDAA-9119-4000-80A9-F217F22C5FF1

Q34571157-020D5502-963C-41B1-A7C0-E88735294CA4

Q34571157-0DA805C2-8CFE-4E94-96D3-E757C5456F53

Q34571157-1098E237-94C3-41DE-85FC-BFDB39606B7F

Q34571157-14E1992E-C18C-4662-8752-8869BC92A2D8

Q34571157-16E7B6FA-475B-4A46-8DC4-D2E50411D238

Q34571157-18F16AB5-4FC2-405B-B2D3-5886DB143409

Q34571157-1A67EB1C-C1C9-47F0-966F-2D429D26E05E

Q34571157-1ACFE149-0492-4F95-9400-DD780E2C54E7

Q34571157-205E651B-0554-4507-899B-A4E5910ED704

P304

Q34571157-EFEF1F1D-1420-433A-8FDD-28429D909EC8

P31

Q34571157-411CC733-6A10-46F8-894A-540A38C13E70

P356

Q34571157-98497DC9-02A4-4F5F-B47D-F42165C5FB67

P407

Q34571157-D4E87A51-6E13-4AC9-A522-06A84BC78F6B

P433

Q34571157-19D53CF1-270F-4704-89C0-F30DDC1AFEE5

P478

Q34571157-E241BBDD-3804-4B27-BB02-292F13B13F11

P50

Q34571157-0FC1222C-F0B6-4629-A639-20F8C860594C

Q34571157-407118A5-E7DD-4F57-B8D9-229DC5BE146B

Q34571157-FE0ADC9B-0C4B-4336-AACE-E9CA950F31D7

P577

Q34571157-3BC329A6-E203-4518-B64E-66BABAF0917E

P698

Q34571157-F25660BA-602D-48E3-BD6C-5676960C5D27

P921

Q34571157-4818F059-EEAD-4668-9C63-C2A60D5385C7

P932

Q34571157-59FC501C-11CE-4754-A6B2-0E3FDE51DA3C

P356

JAMA.299.14.1678

P1433

Journal of the American Medical Association

P1476

Effect of lower targets for bl ...... es: the SANDS randomized trial

@en

P2093

Angela Silverman

http://www.w3.org/2001/XMLSchema#string

Bryce Poolaw

http://www.w3.org/2001/XMLSchema#string

Charlton Wilson

http://www.w3.org/2001/XMLSchema#string

Fawn Yeh

http://www.w3.org/2001/XMLSchema#string

James M Galloway

http://www.w3.org/2001/XMLSchema#string

Jason G Umans

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Henderson

http://www.w3.org/2001/XMLSchema#string

Jerome L Fleg

http://www.w3.org/2001/XMLSchema#string

Jianhui Zhu

http://www.w3.org/2001/XMLSchema#string

Marie Russell

http://www.w3.org/2001/XMLSchema#string

P2860

Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

Hyperglycemia and microvascular and macrovascular disease in diabetes

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

P304

1678-1689

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/JAMA.299.14.1678

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

299

http://www.w3.org/2001/XMLSchema#string

P50

Richard B Devereux

Barbara V Howard

P577

2008-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18398080

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

4243925

http://www.w3.org/2001/XMLSchema#string